Rational design of hybrid hydrazide-hydrazone/thiourea derivatives as potential VEGFR-2 targeting anticancer agents: synthesis, biological evaluation, and mechanistic insights into anticancer activity.
Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways.